Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a novel psoriasis susceptibility locus

被引：0
|
作者：
Merleev, A. [1 ]
Toussi, A. [1 ]
Downing, L. [1 ]
Tran, M. [1 ]
Nava, J. [1 ]
Le, S. [1 ]
Marusina, A. [1 ]
机构：
[1] Univ Calif Davis, Dermatol, Sacramento, CA 95817 USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2021年 / 141卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
005
引用
收藏
页码：S1 / S1
页数：1
相关论文
共 50 条
  • [41] Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After LDL Apheresis
    Tavori, Hagai
    Giunzioni, Ilaria
    Linton, MacRae F.
    Fazio, Sergio
    CIRCULATION, 2013, 128 (22)
  • [42] Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis
    Tavori, Hagai
    Giunzioni, Ilaria
    Linton, MacRae F.
    Fazio, Sergio
    CIRCULATION RESEARCH, 2013, 113 (12) : 1290 - +
  • [43] Procalcific effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) in chronic kidney disease (CKD)
    Ferri, N.
    Lupo, M. G. P.
    Rattazzi, M. R.
    EUROPEAN HEART JOURNAL, 2020, 41 : 3652 - 3652
  • [44] Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice
    Kawakami, Ryo
    Nozato, Yoichi
    Nakagami, Hironori
    Ikeda, Yuka
    Shimamura, Munehisa
    Yoshida, Shota
    Sun, Jiao
    Kawano, Tomohiro
    Takami, Yoichi
    Noma, Takahisa
    Rakugi, Hiromi
    Minamino, Tetsuo
    Morishita, Ryuichi
    PLOS ONE, 2018, 13 (02):
  • [45] Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes
    Liberale, Luca
    Montecucco, Fabrizio
    Camici, Giovanni G.
    Dallegri, Franco
    Vecchie, Alessandra
    Carbone, Federico
    Bonaventura, Aldo
    CURRENT MEDICINAL CHEMISTRY, 2017, 24 (14) : 1403 - 1416
  • [46] Association of serum proprotein convertase Subtilisin/Kexin Type 9 (PCSK9) level with thyroid function disorders
    Yildirim, A. M.
    Koca, A. O.
    Beyan, E.
    Dogan, O.
    Karakaya, S.
    Aksoz, Z.
    Ertugrul, D. T.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (17) : 5511 - 5517
  • [47] Bioactive Cyclization Optimizes the Affinity of a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Peptide Inhibitor
    Tombling, Benjamin J.
    Lammi, Carmen
    Lawrence, Nicole
    Gilding, Edward K.
    Grazioso, Giovanni
    Craik, David J.
    Wang, Conan K.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (05) : 2523 - 2533
  • [48] Modulation of the Vascular Endothelial Inflammatory Response by Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9)
    Leung, A. K.
    Grzelkovski, G.
    Roveran Genga, K.
    Russell, J. A.
    Boyd, J. H.
    Walley, K. R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [49] Discovery and Early Development of Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors
    Piotrowski D.W.
    McInturff E.L.
    ACS Symposium Series, 2019, 1332 : 267 - 296
  • [50] Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9): A new approach in lipid lowering treatment
    Klouras, E.
    Liberopoulos, E.
    Elisaf, M.
    ARCHIVES OF HELLENIC MEDICINE, 2015, 32 (01): : 77 - 84
12345